

# **Opportunity**



**21.7 million** new cancer cases and **13 million cancer deaths** by 2030



Impressive clinical results with checkpoint blockers but only for 20% of patients




**Higher efficacy** expected in combination with **Active Immunotherapies** 




**Innovative Powerful Personalized Immunization Platform** 

**Global Cancer Vaccine Market** 




## **Active Personalized Immunotherapy**



\*ICI: Immune Checkpoint Inhibitors

### **Innovative Powerful Platform**



#### Key differentiator: Combination of 3 important immune players

# **Competitive Positioning**

**15 companies worldwide** in personalized vaccines Ranging from **Preclinical** to most advanced **Phase I/II.** 



	SYNTHETIC PEPTIDE BASED VACCINES	RNA BASED VACCINES	VIRAL VECTORS	odimma
IMMUNOGENICITY	weak and transient	strong but fast degradation	strong but can limit effective delivery	STRONG*
MANUFACTURING	simple	complex	complex	SIMPLE
COST	low	intermediate	high	LOW
TIME TO DELIVERY	fast	long	long	FAST

\*Strong immunity and efficacy obtained in tumor-bearing model (not published yet)



contact@odimma.fr









